8-K - DiaMedica Therapeutics Inc. | StockGist

Current Report Details

Event Type

Management Change+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective Aug

Management Change

Chief Medical Officer of DiaMedica Therapeuti

7.01

and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the United States Securities Exchange Act of 1

Regulation Fd

8.01

Other Events. On July 31, 2025, the Company appointed Julie Krop, M.D., to serve as Chief Medical Officer of the Company, effective as of August 11, 2025. Over

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit Number Description 10.1 Separation Agreement between Dia

Exhibits Only

Source Document

Exhibits (3)

10.1

EXHIBIT 10.1

8-K

FORM 8-K

99.1

EXHIBIT 99.1